SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2023 , Vol. 43 >Issue 2: 646 - 659

DOI: https://doi.org/10.6023/cjoc202207033

Study on Synthesis and Pharmacological Research of Jiyuan Oridonin A Derivatives as Potential Anti-tumor Drugs

  • Ni Wang ,
  • Zijun Zheng ,
  • Xiaoping Jia ,
  • Mengyuan Zhao ,
  • Yalei Wang ,
  • Chen Zhou ,
  • Zhijia Wang ,
  • Zelin Xiao ,
  • Hongmin Liu ,
  • Yu Ke
Expand
  • a Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
    b State Key Laboratory of Esophageal Cancer Prevention & Treatment, Zhengzhou 450001
    c School of Health Sciences, Guangzhou Xinhua College, Guangzhou 510310
* Corresponding authors. E-mail: ;

Received date: 2022-07-03

  Revised date: 2022-10-23

  Online published: 2022-11-08

Supported by

National Natural Sciences Foundations of China(U1904163); Key Research Program of Henan Province(161100311000)

Fold

Abstract

Jiyuan oridonin A (JOA), a diterpenoid ingredient purified from Isodon rubescens collected in Jiyuan, Henan Province, exhibited a variety of anti-tumor activities. In order to further develop the medicinal potency of JOA, a series of its 14-OH benzoate derivatives were designed and synthesized, and then their anti-proliferative activities in vitro were evaluated. The results turned out that the anti-tumor activities of this series of derivatives had been improved compared with the those of JOA, and were much better than that of oridonin. Among them, 7α,20-olide-ent-kaur-16-en-11,15-dione-14β-yl 2-nitro-5- chlorobenzoate (OJW8-9) showed the best activity (IC50=(0.478±0.109) μmol/L on SW-1990 cells). Further studies revealed that compound OJW8-9 inhibited the proliferation of SW-1990 cells by blocking cell cycle in the G2/M phase in a time- and concentration-dependent, and might induce apoptosis through reactive oxygen species (ROS) pathway.

Key words： ent-kaurene diterpene; Jiyuan oridonin A (JOA); anti-proliferative activity; reactive oxygen species (ROS) pathway

Cite this article

Ni Wang , Zijun Zheng , Xiaoping Jia , Mengyuan Zhao , Yalei Wang , Chen Zhou , Zhijia Wang , Zelin Xiao , Hongmin Liu , Yu Ke . Study on Synthesis and Pharmacological Research of Jiyuan Oridonin A Derivatives as Potential Anti-tumor Drugs[J]. Chinese Journal of Organic Chemistry, 2023 , 43(2) : 646 -659 . DOI: 10.6023/cjoc202207033

References

[1]
Sun, H. D.; Huang, S. X.; Han, Q. B. Nat. Prod. Rep. 2006, 23, 673.
[2]
Liu, X.; Yang, J.; Wang, W. G.; Li, Y.; Wu, J. Z.; Pu, J. X.; Sun, H. D. J. Nat. Prod. 2015, 78, 196.
[3]
Yuan, K.; Wu, C. Z.; Zhang, X. Y.; Sun, W.; Zheng, Y. Chin. J. Mod. Appl. Pharm. 2004, 21, 213. (in Chinese)
[3]
(袁珂, 吴崇珍, 张晓明, 孙伟, 郑昱, 中国现代应用药学杂志, 2004, 21, 213.)
[4]
Fujita, E.; Nagao, Y.; Kaneko, K.; Nakazawa, S.; Kuroda, H. Chem. Pharm. Bull. 1976, 24, 2118.
[5]
Fujita, E.; Nagao, Y.; Kohno, T.; Matsuda, M.; Ozaki, M. Chem. Pharm. Bull. 1981, 29, 3208.
[6]
Luo, X.; Pu, J.-X.; Xiao, W.-L.; Zhao, Y.; Gao, X.-M.; Li, X.-N.; Zhang, H.-B.; Wang, Y.-Y.; Li, Y.; Sun, H.-D. J. Nat. Prod. 2010, 73, 1112.
[7]
Han, Q. B.; Zhang, J. X.; Lu, Y.; Wu, Y. S.; Zheng, Q. T.; Sun, H. D. Planta Med. 2004, 70, 581.
[8]
Han, Q. B.; Jiang, B.; Zhang, J. X.; Niu, X. M.; Sun, H. D. Helv. Chim. Acta 2003, 86, 773.
[9]
Cheng, Y.; Qiu, F.; Ye, Y. C.; Tashiro, S.; Onodera, S.; Ikejima, T. Arch. Biochem. Biophys. 2009, 490, 70.
[10]
Bao, R.; Shu, Y.; Wu, X.; Weng, H.; Ding, Q.; Cao, Y.; Li, M.; Mu, J.; Wu, W.; Ding, Q.; Tan, Z.; Liu, T.; Jiang, L.; Hu, Y.; Gu, J.; Liu, Y. BMC Cancer 2014, 14, 217.
[11]
Cheng, Y.; Qiu, F.; Ikejima, T. Autophagy 2009, 5, 430.
[12]
Xia, S.; Zhang, X.; Li, C.; Guan, H. Saudi Pharm. J. 2017, 25, 638.
[13]
Xu, J.; Yang, J.; Ran, Q.; Wang, L.; Liu, J.; Wang, Z.; Wu, X.; Hua, W.; Yuan, S.; Zhang, L.; Shen, M.; Ding, Y. Bioorg. Med. Chem. Lett. 2008, 18, 4741.
[14]
Wang, L.; Li, D.; Xu, S.; Cai, H.; Yao, H.; Zhang, Y.; Jiang, J.; Xu, J. Eur. J. Med. Chem. 2012, 52, 242.
[15]
Li, D.; Han, T.; Tian, K.; Tang, S.; Xu, S.; Hu, X.; Wang, L.; Li, Z.; Hua, H.; Xu, J. Bioorg. Med. Chem. Lett. 2016, 26, 4191.
[16]
Xu, S.; Yao, H.; Luo, S.; Zhang, Y. K.; Yang, D. H.; Li, D.; Wang, G.; Hu, M.; Qiu, Y.; Wu, X.; Yao, H.; Xie, W.; Chen, Z. S.; Xu, J. A J. Med. Chem. 2017, 60, 1449.
[17]
Luo, D.-D.; Peng, K.; Yang, J.-Y.; Piyachaturawat, P.; Saengsawang, W.; Ao, L.; Zhao, W.-Z.; Tang, Y.; Wan, S.-B. RSC Adv. 2018, 8, 29548.
[18]
Luo, D.; Yi, Y.; Peng, K.; Liu, T.; Yang, J.; Liu, S.; Zhao, W.; Qu, X.; Yu, W.; Gu, Y.; Wan, S. Eur. J. Med. Chem. 2019, 178, 365.
[19]
Ke, Y.; Wang, W.; Zhao, L. F.; Liang, J. J.; Liu, Y.; Zhang, X.; Feng, K.; Liu, H. M. Bioorg. Med. Chem. Lett. 2018, 26, 4761.
[20]
Ke, Y.; Liang, J. J.; Hou, R. J.; Li, M. M.; Zhao, L. F.; Wang, W.; Liu, Y.; Xie, H.; Yang, R. H.; Hu, T. X.; Wang, J. Y.; Liu, H. M. Eur. J. Med. Chem. 2018, 157, 1249.
[21]
Xu, S.; Yao, H.; Hu, M.; Li, D.; Zhu, Z.; Xie, W.; Yao, H.; Wu, L.; Chen, Z.S.; Xu, J. J. Nat. Prod. 2017, 80, 2391.
[22]
Yao, H.; Xie, S.; Ma, X.; Liu, J.; Wu, H.; Lin, A.; Yao, H.; Li, D.; Xu, S.; Yang, D.H.; Chen, Z. S.; Xu, J. J. Med. Chem. 2020, 63, 8157.
[23]
Ke, Y.; Hu, T. X.; Huo, J. F.; Yan, J. K.; Wang, J. Y.; Yang, R. H.; Xie, H.; Liu, Y.; Wang, N.; Zheng, Z. J.; Sun, Y. X.; Wang, C.; Du, J.; Liu, H. M. Eur. J. Med. Chem. 2019, 182, 111645.
[24]
Huo, J. F.; Hu, T. X.; Dong, Y. L.; Zhao, J. Z.; Liu, X. J.; Li, L. L.; Zhang, X. Y.; Li, Y. F.; Liu, H. M.; Ke, Y.; Wang, C. Eur. J. Med. Chem. 2020, 208, 112789.
[25]
Yan, X.-B. Ph.D. Dissertation, Zhengzhou University, Zhengzhou, 2002. (in Chinese)
[25]
(闫学斌, 博士论文, 郑州大学, 郑州, 2002.)
Options
Outlines

/

〈 〉